South Korea's Daewoong Pharmaceutical announced on Monday that it has established a drug development system Daewoong AI System (DAISY) which combines an 800 million-compound molecular model database with an artificial intelligence (AI) target substance discovery system.
According to the company, DAISY is an AI drug development portal that enables the discovery of compound substances and rapid prediction of drug properties.
South Korea's Daewoong Pharmaceutical announced on Tuesday that its subsidiary Daewoong Biologics Indonesia has obtained a stem cell Lab Operational License from the Indonesian Ministry of Health.The stem cell processing facility license permits facilities to research and produce stem cells. T
The headquarters of Daewoong Pharmaceutical South Korea's Daewoong Pharmaceutical announced on Monday that it exported its technology for clinical development and commercialization rights of its DWJ108U Depot injection (Leuprolide) product in the US to a UAE-based Zydus Worldwide DMCC.The contr
Daewoong Pharmaceutical, a leading South Korean pharmaceutical company will export its new diabetes drug Envlo Tab. (active ingredient:enavogliflozin), to Russia and the Commonwealth of Independent States (CIS). The company revealed on Friday that it has finalized a contract with JSC Pharmasyn
South Korea's Daewoong Pharmaceutical announced on Tuesday it signed with memorandum of understanding (MOU) with Merck Life Science to build an artificial intelligence (AI)-based new drug development platform and provide technology support the entire cycle of the development process. Merc
South Korea’s Daewoong Pharmaceutical on Wednesday said its gastroesophageal reflux (GER) disease drug Fexuclue (active ingredient fexuprazan hydrochloride) has received product approval from Mexico’s COFEPRIS, or the Federal Committee for Protection from Sanitary Risks.Mexico is t